ACT vs RARE · P/E 9.3, rev $629.4M vs rev $350.0M
Enact Holdings Inc (ACT) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Enact Holdings Inc (ACT) is a insurance - specialty company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported ACT revenue for 2026-06-30 was $629.4M. ACT currently screens at market cap $5.99B and trailing P/E 9.3.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
ACT currently screens at market cap $5.99B and trailing P/E 9.3. RARE currently screens at market cap $2.79B.
Not investment advice. Open the ACT and RARE stock pages for the full models.
Not investment advice.